JUNE 22-28, 2015
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. J.K. Wall reports on some needed successes in clinical trials for experimental drugs, and how Lilly’s strategy has changed. Also in this week’s issue, Scott Olson has the latest on the fate of the former General Motors stamping plant site near downtown, dealt a blow by the cancelled deal for a criminal justice center. And the whole staff teams up for our annual “Indiana 100” publication, a look at the state’s top companies.